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OBJECTIVE — It is much debated whether the metabolic syndrome contributes additional
information over and above that provided by the individual components of the syndrome alone.
Among HIV-infected individuals, we investigated whether any particular combinations of the
components included in the deﬁnition of the metabolic syndrome are associated with a higher
risk of cardiovascular disease (CVD).
RESEARCH DESIGN AND METHODS — We followed 33,347 HIV-infected individ-
uals in a prospective observational study. The effect of combinations of components of the
metabolic syndrome (low HDL cholesterol, high triglycerides, high BMI, hypertension, and
diabetes) on the risk of CVD was assessed by Poisson regression incorporating interactions
between each component pair and adjusting for age, sex, family history of CVD, smoking
status, calendar year, and exposure to antiretroviral therapy. We reduced the risk of type 1
errors by randomly splitting the data set for training (70% of sample) and validation (re-
maining 30%).
RESULTS — In the training data set, 671 patients experienced a CVD event over 110,652
person-years. Unadjusted, the presence of metabolic syndrome at study enrollment (3o ft h e
factors) was associated with a 2.89 higher risk of CVD (95% CI 2.34–3.59; P  0.0001)
comparedwithindividualswithoutthemetabolicsyndrome.Afteradjustmentfortheindividual
components, the metabolic syndrome as an entity no longer predicted the risk of CVD (adjusted
relative risk 0.85; 95% CI 0.61–1.17; P  0.32). No signiﬁcant positive interactions were found
among the components of the metabolic syndrome.
CONCLUSIONS — The presence of the metabolic syndrome in HIV-infected individuals
did not appear to increase the CVD risk over and above that conferred by the components of the
syndrome separately.
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IV-1 infection is treated with com-
bination antiretroviral therapy
(cART). Although treatment is usu-
ally highly effective, the success of treat-
ment is frequently complicated by
lipodystrophy (peripheral fat loss and ac-
cumulation of central adiposity), dyslipi-
demia, insulin resistance, and overt
diabetes (1,2). The clustering of these ab-
normalities has striking similarities to the
metabolic syndrome, a term used to de-
scribe a clustering of risk factors for car-
diovascular disease (CVD), including
high triglycerides, low HDL cholesterol,
hypertension, hyperglycemia/insulin re-
sistance, and abdominal obesity. Prior
studies have reported that the relative fre-
quency of the components of the meta-
bolic syndrome differ between HIV-
infected individuals and the general
population, with hypertriglyceridemia
and low HDL cholesterol being predomi-
nant features in “HIV metabolic syn-
drome” (3,4). However, most of the
studies that have explored the metabolic
syndrome in HIV-infected individuals
have been cross-sectional and have not
considered its relationship with clinical
endpointsassuchasCVD(3,5,6).Several
reports from HIV-infected patients re-
ceiving cART suggested increased inci-
dence of CVD and related mortality (7).
Because many components of the meta-
bolicsyndromemaybeinducedbycART,
it is important to investigate the predic-
tive ability of the metabolic syndrome for
CVD in this population.
The metabolic syndrome is recog-
nized as a “CVD risk enhancer” by the
U.S. National Cholesterol Educational
Program (NCEP) (8), and the presence of
metabolic syndrome is associated with an
increased risk of CVD (9,10). However,
whether the syndrome has any indepen-
dent prognostic value over and above its
components is controversial (11). The
aim of this study was to investigate
whether the presence of the metabolic
syndrome in an HIV-infected individual
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over and above that which would be ex-
pected for the individual given his or her
knownriskfactorsforCVD.Inparticular,
wewishedtoinvestigatewhetheranypar-
ticular combinations of the components
included in the deﬁnition of metabolic
syndrome are associated with a higher
risk of CVD than would be expected from
combining the risk attributable to each
component separately.
RESEARCH DESIGN AND
METHODS— The Data Collection on
Adverse events of Anti-HIV Drugs
(D:A:D) study is a prospective, observa-
tional study formed by the collaboration
of 11 cohorts following 33,347 HIV-
infected subjects at 212 clinics in Europe,
Australia, and the U.S. The primary ob-
jective of the study is to investigate the
possible association between cART and
the onset of myocardial infarction. The
D:A:D study methodology has been de-
scribed in detail elsewhere (12).
Data collection
Patients are followed prospectively dur-
ing visits to outpatient clinics as a part of
regularmedicalcare.Atenrollmentandat
least every 8 months thereafter, standard-
ized data collection forms are completed
at the sites, providing information from
physical examination, patient interview
concerning family history of coronary
heart disease, prior history of CVD and
diabetes, cigarette smoking, blood pres-
sure, lipid-lowering and antihypertensive
therapy, and the presence of physician-
deﬁned lipodystrophy and serum lipid
levels (total cholesterol, HDL cholesterol,
and triglycerides and information on fast-
ing conditions), as well as HIV-related in-
formation (antiviral therapy, CD4 cell
counts, HIV viral loads, and dates of di-
agnoses of all AIDS-deﬁning diseases).
We considered a modiﬁed NCEP def-
inition of the metabolic syndrome (13),
whichincorporatedﬁvecriteria:triglycer-
ides 1.7mmol/l; HDL cholesterol 1.0
mmol/l in men or 1.3 mmol/l in wom-
en; high blood pressure indicated by sys-
tolic blood pressure 130 mmHg or
diastolic blood pressure 85 mmHg;
BMI 30 kg/m
2 as a surrogate of waist
circumference; and a diagnosis of diabe-
tes as a surrogate of fasting glucose. A pa-
tient was deﬁned as having the metabolic
syndrome on the ﬁrst date that at least
three of the ﬁve components were
present. When information was missing
for an individual for any component of
the deﬁnition, that component was as-
sumed to be absent. Furthermore, for our
mainanalyses,thevariouscomponentsof
the metabolic syndrome were assumed to
be irreversible; thus, once an individual
hadmetoneofthecriteria,itwasassumed
that he or she would always meet that
criterion.
Ascertainment of outcomes
All incident cases of myocardial infarc-
tion,allinvasiveproceduresinvolvingthe
coronary arteries (angioplasty or bypass),
and all deaths (irrespective of cause) are
reportedtothecoordinatingofﬁceforval-
idation and coding as described in earlier
reports from the study (14).
The incidence of a composite CVD
end point of myocardial infarction,
stroke, invasive coronary procedure
(ICP), or death from other cardiovascular
cause was calculated by dividing the
number of such events by the total per-
son-years of follow-up in the cohort. Pa-
tient follow-up was counted from the
timeofenrollmentinD:A:Duntilthedate
of the ﬁrst CVD event, 1 February 2007,
or 6 months after the patient’s last clinic
visit.OnlytheﬁrstnewCVDeventduring
prospective follow-up was considered in
the analyses.
Diabetes has been collected as a sec-
ondary D:A:D end point since the start of
the study. New-onset diabetes was con-
sidered as a deﬁnite diagnosis if fasting
plasma glucose 7.0 mmol/l (126 mg/dl)
was measured on two consecutive occa-
sions or as a possible diagnosis if the pa-
tient had a physician-reported date of
diabetes onset and was known to have
initiated antidiabetes therapy.
Statistical analysis
Because of the potential for a high type 1
error rate due to multiple testing, we in-
vestigated the possible presence of inter-
actions between the various components
of the metabolic syndrome in a random
sample of 70% of the cohort (training
sample: n  23,202). Initially, for explor-
atory purposes, patients were grouped on
the basis of their status at entry in D:A:D
into the four strata that resulted from the
combinationofeachcomponentpair,and
the incidence of the CVD end point was
calculated for each strata. We then ex-
plored whether the components of the
deﬁnitionactedsynergisticallyontheend
point by the incorporation of each com-
ponent into a multivariable Poisson re-
gressionanalysisalongwitheachpairwise
interaction term. Any statistically signiﬁ-
cant interaction (P  0.05) with a rate
ratio (RR) 1 would suggest a positive
synergistic effect between the metabolic
syndrome components. These analyses
were adjusted for other potential con-
foundersforCVD(sex,age,familyhistory
of CVD, smoking status, calendar year,
cohort,HIVriskgroup,ethnicgroup,and
exposure to the protease inhibitor, nucle-
oside reverse transcriptase inhibitor
[NRTI], and non-nucleoside reverse tran-
scriptase inhibitor [NNRTI] classes of
drugs).Finally,weexaminedwhetherthe
presence of the metabolic syndrome as an
entity was associated with the risk of
CVD,bothbeforeandaftercontrollingfor
each of the ﬁve individual components of
the deﬁnition and other possible con-
founders as listed above. These analyses
were then repeated using information on
changes over follow-up (a time-updated
analysis) to assess whether the results
were robust to any such changes. To rule
out the possibility that any signiﬁcant in-
teractionsmayhavereﬂectedchanceﬁnd-
ings, the analysis was then repeated using
the remaining 30% of the study cohort
(validation sample: n  10,145).
A series of sensitivity analyses were
performed for the time-updated analyses
on the training set. First, we allowed the
lipidandhypertensioncomponentsofthe
metabolic syndrome to be reversible.
Thus, if a patient experienced a drop
in triglycerides or blood pressure below
the threshold or an increase in HDL cho-
lesterol above the threshold, irrespective
of the cause (including the use of lipid-
lowering or antihypertensive drugs), he
or she no longer met that criterion. Sec-
ondly, we reran the analyses after exclud-
ing follow-up (and events) that occurred
while a patient had incomplete informa-
tion for any metabolic syndrome compo-
nent. Finally, the metabolic syndrome
deﬁnition was further adapted to ensure
that measurements (triglycerides, HDL
cholesterol, or blood pressure) had been
obtained in the previous year; if a patient
did not have a measurement within any
1-year period, he or she was temporarily
excluded from the risk set until a new
measurement became available.
To ensure that our results were not
overly inﬂuenced by patients having dia-
betes and CVD at baseline, the analyses
were repeated after 1) adjustment for
baseline myocardial infarction status
(ﬁxed analyses) and 2) excluding those
with a myocardial infarction and/or dia-
betes at entry in the D:A:D study (time-
updated analyses). The results from these
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those of the primary analyses (data not
shown).
Analyses were performed using the
GENMOD procedure in SAS version 9.1.
P0.05wasconsideredtobestatistically
signiﬁcant.
RESULTS— Of the 23,202 patients in
the training set, 1,025 (4.4%) had the
metabolic syndrome at enrollment (Table
1). The most common components of
the metabolic syndrome at study entry
were elevated triglycerides (95.5% of
those with the metabolic syndrome), low
HDLcholesterol(85.1%),andhighblood
pressure(81.8%).Asexpected,compared
with those without the metabolic syn-
dromeatstudyenrollment,thosewiththe
metabolic syndrome at enrollment were
signiﬁcantly more likely to be male, to be
older, to be current smokers, to have lip-
odystrophy, and to have previously expe-
rienced a myocardial infarction (all P 
0.001). Furthermore, those with the met-
abolicsyndromeatenrollmentweremore
likely to have received the NRTI and pro-
tease inhibitor classes of drugs and had
higher CD4 counts and lower HIV RNA
levels at enrollment than those without
the metabolic syndrome (all P  0.001).
Individuals included in the training set
were followed for a median (range) of 5.1
(3.2–6.5) person-years (total follow-up
110,652 person-years), with no signiﬁcant
difference in follow-up time between those
with and without the metabolic syndrome
at enrollment (P  0.93, Mann-Whitney U
test). Over this time, 671 (2.0%) patients
experienced a CVD event, with the ﬁrst
event being a myocardial infarction in
51.9%, a stroke in 27.9%, an ICP in 18.0%
(angioplasty12.8%,coronarybypass4.3%,
and endarterectomy 0.9%), and cardiovas-
cular death in 2.2%. There were no major
differences in the distribution of ﬁrst events
among those with and without the meta-
bolic syndrome at study enrollment (data
not shown).
Incidence of CVD according to
components of the metabolic
syndrome at study enrollment
When patients were categorized accord-
ing to the presence of the metabolic syn-
drome components at enrollment in the
D:A:D study, event rates ranged from 3.7
(95%CI3.2–4.2)per1,000person-years
amongpatientswithanormaltriglyceride
level and no hypertension to 43.3 (25.2–
69.3) per 1,000 person-years among pa-
tientswithdiabetesandaBMI30kg/m
2
(Table 2). In multivariable analysis ad-
justing for other potential confounders,
there was no evidence of any synergistic
associations between the metabolic syn-
drome component pairs. Whereas weak
negative interactions were noted between
high triglycerides and hypertension and
between low HDL cholesterol and hyper-
tension, these were of borderline signiﬁ-
cance. For example, individuals with low
HDL cholesterol and high blood pressure
appearedtohavealowerriskofCVDthan
would be expected based on the effects of
these factors alone.
The CVD event rate increased as the
number of metabolic syndrome compo-
nents present at study enrollment in-
creased, from 3.2 (95% CI 2.7–3.8) per
1,000person-yearsinthosewithnocom-
ponents present to 33.9 (41.0–122.5) in
those with ﬁve components present. In
unadjusted analyses, the rate of CVD in-
creased by 65% (RR 1.65, 95% CI 1.54–
1.77; P  0.0001) for each additional
component that was present at study en-
rollment; after adjusting for potential
confounders, the effect of an increasing
number of metabolic syndrome compo-
nents remained signiﬁcant (adjusted RR
[ARR] 1.33, 95% CI 1.23–1.44; P 
0.0001). Individuals with the metabolic
syndrome at study enrollment (3o ft h e
factors) were almost three times as likely
(RR 2.89, 95% CI 2.34–3.59; P 
0.0001) to develop CVD as those without
the metabolic syndrome at study enroll-
ment. However, after adjustment for the
components of the metabolic syndrome
themselves and for other potential con-
founders, the metabolic syndrome as an
entitynolongerpredictedtheriskofCVD
(ARR0.85,95%CI0.61–1.17;P0.32).
Incidence of CVD according to
components of the metabolic
syndrome over follow-up
When patients were categorized accord-
ing to the presence of the metabolic syn-
drome components over prospective
follow-up, event rates were lowest in
those with a normal triglyceride level and
normal HDL cholesterol (ARR 1.2, 95%
CI 0.8–1.6 per 1,000 person-years) and
highest in those with diabetes and a BMI
30 kg/m
2 (28.7, 17.7–39.8 per 1,000
person-years) (Table 2).
Table 1—Characteristics at enrollment in D:A:D of the 23,202 patients included in the train-
ing sample
All patients in training
sample
Metabolic syndrome at
enrollment
Yes No
n 23,202 1,025 22,177
Male sex 17,168 (74.0) 853 (83.2) 16,315 (73.6)
Age (years) 38 (33–45) 43 (37–52) 38 (33–44)
CD4 count (cells/mm
3) 410 (249–600) 449 (274–660) 408 (248–598)
HIV RNA (log10 cp/ml) 2.7 (1.7–4.2) 1.9 (1.7–3.5) 2.7 (1.7–4.3)
Current smoker 7,823 (33.7) 410 (40.0) 7,413 (33.4)
Lipodystrophy 4,309 (18.6) 401 (39.1) 3,908 (17.6)
Prior myocardial infarction 172 (0.7) 18 (1.8) 154 (0.7)
Exposure to antiretroviral therapy
Any NRTI 16,928 (73.0) 884 (86.2) 16,044 (72.4)
Total exposure (years) 3.1 (1.6–4.8) 3.6 (2.2–5.3) 3.0 (1.5–4.7)
Any protease inhibitor 13,505 (58.2) 794 (77.5) 12,711 (57.3)
Total exposure (years) 2.3 (1.2–3.2) 2.7 (1.7–3.6) 2.3 (1.2–3.2)
Any NNRTI 7,652 (33.0) 366 (35.7) 7,286 (32.9)
Total exposure (years) 0.9 (0.4–1.6) 1.0 (0.5–1.7) 0.9 (0.4–1.6)
MS components present at
enrollment in D:A:D*
High TRIG 8,923 (38.5) 979 (95.5) 7,944 (35.8)
Low HDL 4,934 (21.3) 872 (85.1) 4,062 (18.3)
High BP 3,278 (14.1) 838 (81.8) 2,440 (11.0)
High BMI 1,019 (4.4) 301 (29.4) 718 (3.2)
Diabetes 651 (2.8) 238 (23.2) 413 (1.9)
Data are n (%) or median (interquartile range). *High triglycerides (TRIG): 1.7 mmol/l; low HDL choles-
terol: 1.0 mmol/l (men) or 1.3 mmol/l (women); high blood pressure (BP): systolic BP 130 mmHg or
diastolic BP 85 mmHg; high BMI: 30 kg/m
2; diabetes: an established diagnosis of diabetes.
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the number of metabolic syndrome com-
ponents present over prospective fol-
low-up increased with rates of 2.3 (95%
CI 1.6–3.0), 3.5 (2.8–4.1), 6.4 (5.6–
7.3), 9.6 (8.3–10.8), 14.4 (10.6–18.2),
and 39.8 (23.6–62.8) per 1,000 person-
years in those with zero, one, two, three,
four, and ﬁve components present, re-
spectively. In unadjusted analyses, the
rate of CVD increased by 64% (RR 1.64,
95% CI 1.53–1.76; P  0.0001) for each
additional component present; after ad-
justment for potential confounders, the
rate of CVD increased by 46% (ARR 1.46,
95% CI 1.34–1.58; P  0.0001) for each
additional component. Before adjust-
ment,individualswiththemetabolicsyn-
drome over follow-up were 2.4 times as
likely (RR 2.40, 95% CI 2.06–2.79; P 
0.0001) to develop CVD than those with-
out the metabolic syndrome (Table 3).
However, as before, after adjustment for
the components of the metabolic syn-
drome themselves and for other potential
confounders, the metabolic syndrome as
an entity no longer predicted the risk of
CVD (ARR 0.94, 95% CI 0.69–1.27; P 
0.67). The results were conﬁrmed in the
validation data set (303 events over
Table 2—CVD incidence rates stratiﬁed by each metabolic syndrome component “pair”
Criterion 1* Criterion 2*
At baseline (ﬁxed) Over follow-up (time-updated)
Rate/1,000 person-years
(95% CI)
Interaction
P value†
Rate/1,000 person-years
(95% CI)
Interaction
P value†
Low TRIG High HDL 4.0 (3.4–4.5) 2.8 (2.2–3.5)
Low TRIG Low HDL 5.9 (4.5–7.2) 1.2 (0.8–1.6)
High TRIG High HDL 7.5 (6.5–8.6) 5.1 (4.3–6.0)
High TRIG Low HDL 10.1 (8.7–11.6) 0.78 8.6 (7.8–9.4) 0.30
Low TRIG No high BP 3.7 (3.2–4.2) 2.4 (1.8–2.9)
Low TRIG High BP 9.1 (6.9–11.3) 5.5 (3.8–7.1)
High TRIG No high BP 8.1 (7.2–9.0) 5.9 (5.2–6.6)
High TRIG High BP 11.1 (8.8–13.4) 0.06‡ 9.3 (8.3–10.4) 0.07
Low TRIG No diabetes 4.0 (3.5–4.5) 2.9 (2.3–3.4)
Low TRIG Diabetes 19.2 (11.7–2.7) 11.0 (4.8–2.2)
High TRIG No diabetes 7.5 (6.7–8.3) 6.4 (5.9–7.0)
High TRIG Diabetes 39.2 (29.5–48.8) 0.19 25.9 (20.8–31.1) 0.23
Low TRIG Low BMI 4.3 (3.8–4.8) 2.9 (2.3–3.5)
Low TRIG High BMI 4.8 (2.6–8.2) 5.2 (2.7–9.0)
High TRIG Low BMI 8.3 (7.5–9.2) 7.2 (6.5–7.8)
High TRIG High BMI 15.1 (9.7–20.5) 0.38 10.1 (7.5.12.8) 0.14
High HDL No high BP 4.5 (4.0–5.0) 3.2 (2.7–3.8)
High HDL High BP 10.1 (8.0–12.1) 6.7 (5.2–8.2)
Low HDL No high BP 8.0 (6.9–9.1) 6.3 (5.4–7.2)
Low HDL High BP 10.3 (7.9–12.8) 0.04‡ 9.4 (8.3–10.6) 0.05‡
High HDL No diabetes 4.7 (4.2–5.1) 3.7 (3.1–4.2)
High HDL Diabetes 24.7 (17.5–31.9) 17.8 (10.9–24.6)
Low HDL No diabetes 7.3 (6.4–8.3) 6.8 (6.2–7.5)
Low HDL Diabetes 39.4 (27.6–51.2) 0.80 26.3 (20.5–32.1) 0.53
High HDL Low BMI 5.0 (4.5–5.5) 4.0 (3.4–4.5)
High HDL High BMI 7.3 (4.5–10.2) 5.0 (2.8–7.1)
Low HDL Low BMI 8.2 (7.2–9.2) 7.5 (6.8–8.2)
Low HDL High BMI 14.8 (8.6–23.6) 0.52 12.6 (9.0–16.2) 0.32
No high BP No diabetes 4.9 (4.4–5.3) 4.1 (3.6–4.6)
No high BP Diabetes 27.9 (20.8–35.0) 20.7 (14.2–27.2)
High BP No diabetes 8.8 (7.3–10.3) 7.5 (6.6–8.4)
High BP Diabetes 36.3 (23.1–49.6) 0.55 25.5 (19.4–31.7) 0.21
No high BP Low BMI 5.3 (4.8–5.8) 4.6 (4.0–5.1)
No high BP High BMI 8.3 (5.2–11.4) 4.8 (2.9–7.6)
High BP Low BMI 10.1 (8.4–11.7) 8.2 (7.3–9.2)
High BP High BMI 11.4 (5.6–17.1) 0.23 12.1 (8.8–15.5) 0.43
No diabetes Low BMI 5.4 (4.9–5.8) 5.3 (4.8–5.7)
No diabetes High BMI 6.0 (3.7–8.4) 6.1 (4.2–7.9)
Diabetes Low BMI 28.2 (21.6–34.7) 22.2 (17.3–27.1)
Diabetes High BMI 43.3 (25.2–69.3) 0.12 28.7 (17.7–39.8) 0.44
DataareCVDincidenceratesper1,000personyears(95%CI).*Hightriglycerides(TRIG):1.7mmol/l;lowHDLcholesterol:1.0mmol/l(men)or1.3mmol/l
(women);highbloodpressure(BP):systolicBP130mmHgordiastolicBP85mmHg;diabetes:anestablisheddiagnosisofdiabetes.†Pvaluesfortheinteraction
between each component pair were obtained from a multivariable Poisson regression model that included all main effects and all pairwise interactions, as well as
adjustment for other potential confounders (see RESEARCH DESIGN AND METHODS). ‡ARRs were all 1, suggesting an antagonistic rather than synergistic effect of each
combination of components.
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analyses reached similar conclusions (Ta-
ble 3).
Inthemainanalyses,ofthemetabolic
syndrome components diabetes was the
strongest independent predictor of CVD
with an ARR of 2.31 (95% CI 1.83–2.92;
P  0.0001) followed by high triglycer-
ides (1.50, 1.18–1.91; P  0.001) and
low HDL cholesterol (1.41, 1.12–1.76;
P  0.003). A high BMI was more weakly
associated with CVD (1.33, 1.01–1.74;
P  0.04), whereas high blood pressure
was not independently associated with
the risk of CVD (1.26, 0.98–1.62; P 
0.07).Similarresultswereobtainedinthe
validation data set (Table 3).
CONCLUSIONS — There is a strong
associationbetweenthepresenceofanin-
creasingnumberofthecomponentsofthe
metabolic syndrome in HIV-infected pa-
tients and an increased CVD risk in the
D:A:D study. In particular, the CVD rate
was 2.4–2.8 times higher in those with
the metabolic syndrome than in those
without the metabolic syndrome. How-
ever, there was no evidence from our
study that the metabolic syndrome as a
speciﬁc entity was associated with a
higher CVD risk than would be antici-
pated based on the presence of the indi-
vidual components alone. In particular,
there was no evidence that any of the
components of the metabolic syndrome
acted synergistically on an individual’s
risk of CVD, and the presence of the met-
abolic syndrome did not increase CVD
risk over and above that conferred by the
components of the syndrome. The results
from our sensitivity analyses, which ex-
plored the robustness of the ﬁndings to
missing data and to changes in lipid and
blood pressure measurements, were all
consistent with our main analyses.
The components included in the def-
inition of the metabolic syndrome are all
established independent risk factors for
CVD in populations not infected with
HIV. If the metabolic syndrome provides
additional information on the CVD risk
over and above that provided by these
components separately, we would expect
to see some synergism between the com-
ponents.Sofar,onlyafewstudiesexplor-
ing the predictive ability of metabolic
syndrome on a CVD outcome have spe-
ciﬁcally addressed this question by ad-
justing for the components of the
syndrome. These studies either showed
lower hazard ratios for the metabolic syn-
drome compared with the individual risk
factors or showed that metabolic syn-
drome by itself does not contribute any
additional information (15–17).
To date, although several studies of
HIV-infected individuals have assessed
the impact of the various components of
the metabolic syndrome on the risk of
CVD, no study has been able to consider
the impact of the metabolic syndrome it-
self on clinical end points. However, data
from a post hoc analysis of the naive sub-
study of the INITIO trial (based on 21
CVD events) suggested that incident met-
abolic syndrome was associated with
CVD with a hazard ratio of 2.56 (95% CI
0.86–7.60)(18).Thisresultdidnotreach
statistical signiﬁcance and, as noted by
the authors, should be interpreted with
caution. With the aging of the HIV-
infected population, brought about by an
increased life expectancy after the wide-
spread use of cART, it is likely that the
long-term metabolic complications
among HIV-infected individuals will
place this group at risk of CVD in the fu-
ture. An increasing number of HIV-
infected patients are starting to develop
diabetes (19). The results from the
present analysis conﬁrm our previous
ﬁnding that diabetes is an important risk
factor for myocardial infarction and CVD
among HIV-infected individuals (12). Al-
though dyslipidemia remains an impor-
tant predictor of CVD, this condition
appears to be decreasing in frequency,
largely due to increased use of lipid-
lowering drugs (19).
We have recently reported an in-
creased risk of myocardial infarction as-
sociated with the use of the protease
inhibitor drug class (12), which was
partly explained by dyslipidemia. From
theNRTIdrugclass,abacavirwasrecently
reportedtobeassociatedwithmyocardial
infarction and CVD (20,21), which might
be due to changes in inﬂammation, i.e.,
interleukin-6andhigh-sensitivityC-reac-
tive protein (21). Both biomarkers are in-
dependently associated with CVD
(15,22). Increased inﬂammation is re-
portedtobeassociatedwiththemetabolic
syndrome among HIV-infected (6) and
uninfected (15) individuals. However,
neither C-reactive protein nor other bi-
omarkers are included in the deﬁnition of
the metabolic syndrome, although the in-
clusion of such biomarkers may provide
useful information. Unfortunately, the
D:A:D study does not collect information
on these biomarkers, so it is unclear
whether their inclusion would have
Table 3—Association between the metabolic syndrome (time-updated analyses), its components, and CVD from main and sensitivity analyses
Factor*
Main analysis: training
set (671 events, 110,652
person-years)
Main analysis: validation
set (303 events, 48,741
person-years)
Metabolic syndrome
components reversible
(671 events, 110,652
person-years)
No missing data on
metabolic syndrome
components (377 events,
57,536 person-years)
Unadjusted
MS 2.40 (2.06–2.79); 0.0001 2.71 (2.16–3.40); 0.0001 3.02 (2.54–3.59); 0.0001 3.34 (2.36–4.74); 0.0001
Adjusted†
MS 0.94 (0.69–1.27); 0.67 1.00 (0.64–1.57); 0.99 1.03 (0.77–1.39); 0.83 0.88 (0.52–1.49); 0.63
High TRIG 1.50 (1.18–1.91); 0.001 1.26 (0.88–1.79); 0.20 1.47 (1.23–1.76); 0.0001 1.39 (1.10–1.76); 0.006
Low HDL 1.41 (1.12–1.76); 0.003 1.61 (1.12–2.30); 0.009 1.25 (1.03–1.51); 0.02 1.44 (1.12–1.86); 0.005
High BP 1.26 (0.98–1.62); 0.07 1.40 (0.95–2.05); 0.09 1.14 (0.92–1.41); 0.23 1.23 (0.98–1.53); 0.07
Diabetes 2.31 (1.83–2.92); 0.0001 1.96 (1.39–2.77); 0.0001 2.27 (1.77–2.92); 0.0001 2.07 (1.43–2.99); 0.0001
High BMI 1.33 (1.01–1.74); 0.04 1.38 (0.94–2.03); 0.10 1.13 (0.79–1.60); 0.51 1.09 (0.67–1.79); 0.72
DataareARRs(95%CI);Pvalues.*Hightriglycerides(TRIG):1.7mmol/l;lowHDLcholesterol:1.0mmol/l(men)or1.3mmol/l(women);highbloodpressure
(BP): systolic BP 130 mmHg or diastolic BP 85 mmHg; diabetes: an established diagnosis of diabetes; high BMI: 30 kg/m
2. †Adjusted estimates obtained from
a multivariable Poisson regression model that also includes adjustment for other potential confounders as sex, age, family history of CVD, smoking status, calendar
year, cohort, HIV risk group, ethnic group, and exposure to the protease inhibitor, NRTI, and NNRTI classes of drugs.
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will provide further insight into HIV-
induced as well as antiretroviral therapy–
induced inﬂammation.
The debate about the existence of the
metabolic syndrome as an entity and its
prognostic value is ongoing (11,23,24).
Some of the critique has focused on the
independent predictive ability of the met-
abolic syndrome for CVD. We aimed in
thisstudytoinvestigatewhetherthepres-
ence of the metabolic syndrome in an
HIV-infected individual constitutes an
additional risk for CVD, over and above
that which would be expected in the in-
dividual given his or her known risk fac-
tors for CVD. A priori, we believed that
certain combinations of risk factors
would be more frequent than others. If
these combinations were of any indepen-
dent prognostic information, we would
then expect to ﬁnd positive interactions
between these risk factor combinations
(i.e., the presence of both factors would
beassociatedwithagreaterthanexpected
increase in the risk of CVD). However,
this was not the case. Even by including
“overt diabetes” in the syndrome deﬁni-
tion instead of fasting glucose, we still did
not ﬁnd the metabolic syndrome as an
independent predictor of CVD. We do
not believe that the inclusion of fasting
glucose would have resulted in major
differences.
Limitations
Our study population is largely male
(70%), and so our results should be ex-
trapolated to women with some caution.
As the D:A:D study does not collect waist
circumference, we used increased BMI to
reﬂect this component of the metabolic
syndrome, as in other studies (17). The
use of BMI may have resulted in lower
estimated effects compared with waist
circumference, because BMI includes to-
tal fat mass. However, it has been sug-
gested that waist circumference more
closely reﬂects visceral fat mass that is di-
rectly related to insulin resistance (6).
Furthermore, the lipodystrophic changes
with central fat accumulation and loss of
peripheral subcutaneous fat may under-
estimate the prevalence of the metabolic
syndrome, as these patients may have a
normal BMI and might not have been
sufﬁciently captured by our modiﬁed
NCEP deﬁnition. Furthermore, many of
themetabolicchangesinHIVareinduced
by antiretroviral therapy, and their im-
pact on CVD risk may differ from that in
thegeneralpopulation.Ofnote,measure-
ments of hypertension and lipids were
generally obtained through routine clini-
calcareand,assuch,arenotalwaysbased
onthestandardizedprotocolsthatmaybe
used in a trial setting. As a result, we may
haveoverestimatedthefrequencyofthese
conditions in this study.
In summary, we did not ﬁnd that the
metabolic syndrome was an independent
predictorofCVDinHIV-infectedindivid-
ualsoncewehadconsideredtheriskcon-
ferred by the components of the
syndrome. However, we found a strong
association between an increasing num-
ber of the components of the metabolic
syndromeandCVDrisk,emphasizingthe
importanceoftheidentiﬁcationandman-
agement of all CVD factors in this popu-
lation,includingthosenotincludedinthe
metabolic syndrome deﬁnition (e.g.,
smoking); the identiﬁcation of one CVD
risk factor should immediately lead the
physician to search for other CVD risk
factors. Patients should also be evaluated
for CVD risk at least annually (25).
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